MINI FUTURE LONG - ORION B | Real-time Bid/Ask 09:12:29 14/06/2024 BST | ||
| 0.47 EUR / 0.48 EUR | +10.47% |
|
| Current month | -10.42% | ||
| 1 month | -2.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ORION OYJ
Latest news about ORION OYJ
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.42 | -2.33% |
| 13/06/24 | 0.43 | -14.00% |
| 12/06/24 | 0.5 | +11.11% |
| 11/06/24 | 0.45 | -19.64% |
| 10/06/24 | 0.56 | -6.67% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 07:49 am
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ORION OYJ |
| Issuer | Morgan Stanley |
| WKN | MG3AZR |
| ISIN | DE000MG3AZR2 |
| Date issued | 30/04/2024 |
| Strike | 32.72 € |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.64 € |
|---|---|
| Lowest since issue | 0.31 € |
| Spread | 0.01 € |
| Spread % | 2.08% |
Company Profile
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows:
- generic, OTC and biosimilar drugs (43.4%);
- patented prescription products (41.7%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments;
- animal health products (8.7%);
- pharmaceutical ingredients and outsourcing services (6.2%).
Net sales break down primarily by source of revenue between sales of products (86.9%) and royalties (10.4%).
Net sales are distributed geographically as follows: Finland (28%), Scandinavia (12%), Europe (30.8%), North America (14.7%) and other (14.5%).
Sector
-
Consensus: Orion Oyj
Sell
Buy
Mean consensus
HOLD
Number of Analysts
6
Last Close Price
37.09
EUR
Average target price
38.2
EUR
Spread / Average Target
+2.99%
- Stock Market
- Certificates
- Certificat
